HomeGRAL • NASDAQ
add
Grail Inc
Nakaraang pagsara
$99.80
Sakop ng araw
$96.03 - $100.00
Sakop ng taon
$16.10 - $115.76
Market cap
3.81B USD
Average na Volume
1.13M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 36.19M | 26.32% |
Gastos sa pagpapatakbo | 145.03M | -25.53% |
Net na kita | -88.98M | 29.21% |
Net profit margin | -245.83 | 43.96% |
Kita sa bawat share | -2.46 | 29.77% |
EBITDA | -86.31M | 40.18% |
Aktuwal na % ng binabayarang buwis | 25.05% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 540.13M | -36.72% |
Kabuuang asset | 2.60B | -16.58% |
Kabuuang sagutin | 361.07M | -31.91% |
Kabuuang equity | 2.24B | — |
Natitirang share | 38.98M | — |
Presyo para makapag-book | 1.61 | — |
Return on assets | -11.81% | — |
Return on capital | -13.40% | — |
Cash Flow
Net change in cash
| (USD) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -88.98M | 29.21% |
Cash mula sa mga operasyon | -63.24M | 39.53% |
Cash mula sa pag-invest | 66.67M | 6,966.43% |
Cash mula sa financing | — | — |
Net change in cash | 3.09M | 102.93% |
Malayang cash flow | -19.27M | 60.50% |
Tungkol
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.
In June 2021 Galleri launched their liquid biopsy, or multi-cancer early detection test, which they called Galleri test. In 2023 EU regulators ordered Grail to be spun-out from Illumina which was completed on June 24, 2024. Wikipedia
Itinatag
2015
Headquarters
Website
Mga Empleyado
1,000
